untitled design

Pfizer claims Covid-19 vaccine is long-term effective in adolescents

Drugmaker Pfizer said on Monday (22) that its Covid-19 vaccine offered strong long-term protection against the virus in an advanced-stage study conducted with 12- to 15-year-olds.

A series of two doses of the vaccine was 100% effective against Covid-19, monitored from seven days to more than four months after the second dose, the company said.

Long-term data will support scheduled submissions for full regulatory approval of the vaccine for this age group in the United States and around the world.

Pfizer and BioNTech will seek clearance to apply a 30-microgram dose of the vaccine to people 12 years of age and older.

The vaccine was authorized for emergency use in adolescents aged 12 to 15 years by the US Food and Drug Administration (FDA) in May, and obtained full approval for use in people aged 16 years and older in August.

(*With information from Agência Brasil)

Reference: CNN Brasil

You may also like

NZD/USD falls on dovish RBNZ stance
Markets
Joshua

NZD/USD falls on dovish RBNZ stance

RBNZ Governor Orr was dovish, which seems to put pressure on the New Zealand Dollar. GDP and initial jobless claims

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular